We are live on ! Find out more
Birchview Capital

Birchview Capital Portfolio holdings

AUM $173M Turnover 41.05%
1-Year Est. Return 89.27%
This Fund
S&P 500
This Quarter Est. Return
+4.89%
1 Year Est. Return
+89.27%
3 Year Est. Return
+315.46%
5 Year Est. Return
+442.13%
10 Year Est. Return
+979.78%
AUM
$189M
AUM Growth
-$1.06M
Cap. Flow
-$5.94M
Cap. Flow %
-3.14%
Top 10 Hldgs %
89.07%
Holding
42
New
4
Increased
5
Reduced
4
Closed
1
Avg Time Held
0.4 years
Top 10 Avg Time Held
0.5 years
Top 20 Avg Time Held
0.4 years

Sector Composition

Rank Sector Weight
1 Healthcare 85.88%
2 Miscellaneous 5.16%
3 Energy 4.71%
4 Consumer Staples 4.04%
5 Technology 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
CELG
1
DELISTED
Celgene
CELG
$84.8M 44.79%
732,553
-107,610
-13% -$12.3M
2014 Q4
2 quarters
AXDX icon
2
DELISTED
Accelerate Diagnostics
AXDX
$53.4M 28.19%
206,756
– –
2014 Q4
2 quarters
YTEN icon
3
DELISTED
Yield10 Bioscience
YTEN
$7.64M 4.04%
236
+15
+7% +$617K
2014 Q4
2 quarters
VRML
4
DELISTED
Vermillion
VRML
$5.62M 2.97%
2,717,514
– –
2014 Q4
2 quarters
HNSN
5
DELISTED
Hansen Medical
HNSN
$4.83M 2.55%
528,144
+236,051
+81% +$2.15M
2014 Q4
2 quarters
EQT icon
6
EQT
EQT
$30.9B
$3.36M 1.77%
75,868
– –
2014 Q4
2 quarters
MDVN
7
DELISTED
Medivation
MDVN
$2.48M 1.31%
43,360
– –
2014 Q4
2 quarters
SWN icon
8
DELISTED
Southwestern Energy
SWN
$2.19M 1.16%
96,483
– –
2014 Q4
2 quarters
GILD icon
9
Gilead Sciences
GILD
$209B
$2.19M 1.15%
18,670
– –
2014 Q4
2 quarters
CFRX
10
DELISTED
ContraFect
CFRX
$2.15M 1.14%
+569
New +$2.31M
2015 Q2
0 quarters
BIOL icon
11
DELISTED
Biolase
BIOL
$2.06M 1.09%
95
– –
2014 Q4
2 quarters
MASI icon
12
DELISTED
Masimo
MASI
$1.42M 0.75%
36,600
– –
2014 Q4
2 quarters
COLL icon
13
Collegium Pharmaceutical
COLL
$776M
$1.4M 0.74%
+78,768
New +$1.36M
2015 Q2
0 quarters
CLR
14
DELISTED
Continental Resources
CLR
$1.38M 0.73%
32,674
– –
2014 Q4
2 quarters
OMED
15
DELISTED
OncoMed Pharmaceuticals
OMED
$1.32M 0.7%
58,689
+14,000
+31% +$345K
2014 Q4
2 quarters
OVV icon
16
Ovintiv
OVV
$16.5B
$896K 0.47%
16,260
+2,320
+17% +$148K
2014 Q4
2 quarters
QDEL icon
17
QuidelOrtho
QDEL
$575M
$894K 0.47%
38,975
– –
2014 Q4
2 quarters
AEGR
18
DELISTED
Aegerion Pharmaceuticals
AEGR
$873K 0.46%
46,000
– –
2015 Q1
1 quarter
MRK icon
19
Merck
MRK
$332B
$854K 0.45%
15,720
– –
2014 Q4
2 quarters
PTCT icon
20
PTC Therapeutics
PTCT
$4.81B
$813K 0.43%
16,900
– –
2014 Q4
2 quarters
ARAY icon
21
Accuray
ARAY
$6.45M
$811K 0.43%
3,008
– –
2014 Q4
2 quarters
TRNX
22
DELISTED
Tornier
TRNX
$750K 0.4%
30,000
– –
2014 Q4
2 quarters
RPTP
23
DELISTED
Raptor Pharmaceutical
RPTP
$726K 0.38%
46,000
+16,000
+53% +$194K
2015 Q1
1 quarter
ADXS
24
DELISTED
Advaxis Inc
ADXS
$724K 0.38%
+2,373
New +$750K
2015 Q2
0 quarters
CTRA icon
25
DELISTED
Coterra Energy
CTRA
$662K 0.35%
21,000
– –
2014 Q4
2 quarters

Similar funds

Birchview Capital's Q2 2015 Portfolio in Review

As of Q2 2015, Birchview Capital held 42 positions worth $189M, down 0.56% from $190M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Birchview Capital withdrew a net $5.94M in Q2 2015, closing 1 position and reducing 4 holdings. Its most notable exit was Auspex Pharmaceuticals, an estimated $902K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 86% a quarter earlier, followed by Miscellaneous and Energy.

Against the trend, Birchview Capital opened a new position in ContraFect worth $2.15M.

  • Birchview Capital's largest Q2 2015 buy was ContraFect: 569 shares worth $2.15M.
  • Birchview Capital added most to Hansen Medical in Q2 2015, an estimated $2.15M increase.
  • Birchview Capital's biggest Q2 2015 reduction was Celgene, cutting an estimated $12.3M.
  • Birchview Capital fully exited Auspex Pharmaceuticals in Q2 2015, selling an estimated $902K.
  • Birchview Capital's ten largest holdings make up 89% of its $189M portfolio in Q2 2015.
  • Birchview Capital opened 4 new positions and closed 1 in Q2 2015.
  • Birchview Capital's portfolio value fell 0.56% quarter-over-quarter to $189M.

Based on Birchview Capital's 13F filing for Q2 2015, filed 13 Aug 2015.